Long-term Outcome of Intravitreal Ranibizumab Treatment, Compared with Photodynamic Therapy, in Patients with Polypoidal Choroidal Vasculopathy

Long-term Outcome of Intravitreal Ranibizumab Treatment, Compared with Photodynamic Therapy, in Patients with Polypoidal Choroidal Vasculopathy - Long-term outcome of IVR for PCV

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000008630

Enrollment

Registered

2012-08-06

Start date

2012-08-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polypoidal choroidal vasculopathy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients were initially treated with IVR or PDT at the Yokohama City University Medical Center between September 2005 and June 2010. The inclusion criteria were the presence of PCV; a treatment-na&iuml;ve status; availability for follow-up at 24 months or longer after the first treatment; and a BCVA of 20/400 or better at baseline.

Exclusion criteria

Exclusion criteria: Patients who underwent PDT that was subsequently switched to ranibizumab monotherapy within 2 years were also excluded. Patients with eye diseases that could potentially influence visual acuity.

Design outcomes

Primary

Measure	Time frame
The BCVA between the pre- and postoperative BCVA at 3, 6, 12, 18, and 24 months after the initial treatment.	—

Secondary

Measure	Time frame
The differences between the pre- and postoperative BCVA. The regression of polyps Complications	—

Countries

Japan

Contacts

Public ContactMaiko Inoue

Yokohama City University Medical Center Ophthalmology

045-261-5656

Outcome results